Stock Taper
OGN
ORGANON & CO.
NYSE
$13.81
▲ UP 0.44% (0.06)

KEY STATISTICS

Market Cap$3.62 B
52w High$13.83
52w Low$5.69
Dividend Yield0.59%
FrequencyQuarterly
P/E4.12
Volume3.26M
Shares Out.262.61M

COMPANY

LEADERSHIP

Joseph T. Morrissey Jr.
CHIEF EXECUTIVE
Joseph T. Morrissey Jr.

COMPENSATION 2026

Salary$819,231
Stock Awards$3,365,818
Incentive Plan Pay$602,433
All Other Comp.$235,368
Total$5,772,848

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 14, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
10,000

PRICE TARGET

Target High$14.00
Target Low$12.00
Target Median$13.00
Target Consensus$13.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$1.58B
NOV
9
MON

ETFS HOLDING THIS STOCK

ETFS HOLDING
226
LISTED HERE
10
RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
59.22%
HOLDERS
990
TOP 8 OF 990 · RANKED BY POSITION SIZE

PRICE

$13.81 ▲ UP 0.44% (+$0.06)
$13.75$13.78$13.80$13.839:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM13.81

About Organon & Co.

https://www.organon.com ↗

Organon & Co. develops global health solutions across women’s health, biosimilars, oncology, cardiovascular, respiratory, dermatology, and other therapies, primarily selling to healthcare providers, hospitals, and government agencies.

INDUSTRY

Drug Manufacturers - General

A PRODUCT ORGANON & CO. IS KNOWN FOR

Nexplanon
Nexplanon

Organon's flagship long-acting, reversible contraceptive implant, placed under the upper arm and effective for up to three years, is a key product driving the company's women's health portfolio.

Organon & in 2025

SENTIMENT: − NEGATIVE
Audit Committee of the Board
LEGAL · OCTOBER 27, 2025

Organon CEO Resigns Amid Investigation into Improper Sales Practices, Stock Plummets 23%

Organon's CEO, Kevin Ali, resigned abruptly on October 27, 2025, following an internal investigation that uncovered 'improper' wholesale sales practices related to its key contraceptive product, Nexplanon. The investigation found that the company encouraged wholesalers to purchase more products than needed to meet revenue expectations, a practice commonly known as 'channel stuffing'.

CAPITAL ALLOCATION · Q1 2025 · IN PROGRESS

Organon Pivots to Aggressive Deleveraging, Slashes Dividend to Fortify Balance Sheet

In a major strategic shift, Organon's leadership reset its capital allocation priorities to aggressively reduce debt, aiming for a net leverage ratio below 4.0x by the end of 2025. This move was underscored by a significant reduction in the company's quarterly dividend, freeing up capital to strengthen its financial position for long-term growth.

Latest News

ACCESSWIRE · OCT 8, 2026

Orogen Royalties Creates a Royalty on the Cibola Copper-Gold Project in British Columbia

VANCOUVER, BC / ACCESS Newswire / October 8, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce that it has signed a purchase and sale agreement (the "Agreement") with Northern Discovery Metals (CSE:NOR) ("Northern") whereby Northern will acquire a 100% interest in the Cibola copper-gold porphyry project in British Columbia, Canada. Under the terms of the Agreement, Northern will pay to Orogen $130,000 and issue 700,000 common shares of Northern.

EARLIER COVERAGE
ZACKS INVESTMENT RESEARCH · OCT 2, 2026

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

BUSINESS WIRE · OCT 1, 2026

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets4
Debt To Equity1
Price To Earnings3
Price To Book2
Overall Score3

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 2
UNDERWEIGHT 2
EQUAL WEIGHT 1
5 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
GRDN$41.35COMPARE
HRMY$39.77COMPARE
MD$26.22COMPARE
AUPH$16.17COMPARE
ALVO$5.63COMPARE
NUVB$4.75COMPARE
PAHC$37.38COMPARE
TLRY$3.59COMPARE

TRADES BY CONGRESS

HOUSE TRADES
Kevin Hern
Kevin Hern
Sale (Full)
2026-08-05
SENATE TRADES
Gary C. Peters
Gary C. Peters
Sale
2025-10-07
Gary Peters
Gary Peters
Sale
2025-10-07
HOUSE TRADES
Ro Khanna
Ro Khanna
Sale
2023-11-03

INSIDER TRADES

★
OFFICER: HEAD OF R&D & CMO
Arjona Ferreira Juan Camilo
Purchase · 11.5K shares
2026-08-11
★
OFFICER: HEAD OF R&D & CMO
Arjona Ferreira Juan Camilo
Sale · 4.1K shares
2026-08-11
★
OFFICER: HEAD OF R&D & CMO
Arjona Ferreira Juan Camilo
Purchase · 11.5K shares
2026-08-11
★
OFFICER: HEAD OF MFG & SUPPLY
Drinane Juliana Papa
Sale · 14.8K shares
2026-08-05